Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry

被引：0
作者：
Helen E. Jo
Ian Glaspole
Yuben Moodley
Sally Chapman
Samantha Ellis
Nicole Goh
Peter Hopkins
Greg Keir
Annabelle Mahar
Wendy Cooper
Paul Reynolds
E. Haydn Walters
Christopher Zappala
Christopher Grainge
Heather Allan
Sacha Macansh
Tamera J. Corte
机构：
[1] Royal Prince Alfred Hospital,School of Medicine
[2] University of Sydney,School of Medicine
[3] The Alfred Hospital,undefined
[4] Fiona Stanley Hospital,undefined
[5] Royal Adelaide Hospital,undefined
[6] The Austin Hospital,undefined
[7] Prince Charles Hospital,undefined
[8] Princess Alexandria Hospital,undefined
[9] Western Sydney University,undefined
[10] University of Tasmania,undefined
[11] University of Tasmania,undefined
[12] Royal Brisbane and Women’s Hospital,undefined
[13] John Hunter Hospital,undefined
[14] Lung Foundation Australia,undefined
来源：
BMC Pulmonary Medicine | / 18卷
关键词：
Idiopathic pulmonary fibrosis; Interstitial lung disease; Disease severity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 143 条
[1]  
Raghu G(2011)An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management Am J Respir Crit Care Med 183 788-824
[2]  
Collard HR(2015)Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review Eur Respir J 46 795-806
[3]  
Egan JJ(2014)A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N Engl J Med 370 2083-2092
[4]  
Martinez FJ(2014)Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis N Engl J Med 370 2071-2082
[5]  
Behr J(2016)Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Eur Respir J 47 243-253
[6]  
Brown KK(2016)Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials Respir Med 113 74-79
[7]  
Colby TV(2017)Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume Thorax 72 340-346
[8]  
Cordier JF(2016)Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function Eur Respir J 48 843-851
[9]  
Flaherty KR(2014)Staging of idiopathic pulmonary fibrosis: past, present and future Eur Respir Rev 23 220-224
[10]  
Lasky JA(2017)A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis ERJ open research 3 1-1181
12345678910